Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities.
Li HY, Chen YL, Deng XN, Li HH, Tan J, Liu GJ, Zheng YJ, Pei M, Peng KT, Yue LL, Chen XJ, Liu Y, Zhao YS, Wang CH.
Li HY, et al. Among authors: chen xj, chen yl.
Acta Pharmacol Sin. 2023 Nov;44(11):2322-2330. doi: 10.1038/s41401-023-01118-2. Epub 2023 Jun 16.
Acta Pharmacol Sin. 2023.
PMID: 37328649